Mini-Tumors grown in lab could unlock colon cancer resistance secrets

NCT ID NCT05038358

Recruiting now Knowledge-focused Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study collects tumor samples from 60 patients with colorectal cancer before they receive any chemotherapy. Researchers will grow mini-tumors (organoids) in the lab to study how the immune system and tumor cells interact. The goal is to understand why 30-50% of patients do not respond to chemotherapy from the start, which could lead to better personalized treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could identify new markers to predict chemotherapy resistance and pave the way for personalized treatments for colorectal cancer.
What could go wrong: This is an early-stage observational study with only 60 participants. It focuses on lab research, not direct patient treatment, so benefits may take years to materialize.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON TUMOR PRIMARY TUMOR

Contacts and locations

Locations

University Hospital of Grenoble Alpes
RECRUITING

Grenoble, 38043, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.